KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBIT Margin (2017 - 2025)

Sarepta Therapeutics has reported EBIT Margin over the past 12 years, most recently at 92.92% for Q4 2025.

  • Quarterly results put EBIT Margin at 92.92% for Q4 2025, down 11748.0% from a year ago — trailing twelve months through Dec 2025 was 31.83% (down 4330.0% YoY), and the annual figure for FY2025 was 31.83%, down 4330.0%.
  • EBIT Margin for Q4 2025 was 92.92% at Sarepta Therapeutics, down from 25.89% in the prior quarter.
  • Over the last five years, EBIT Margin for SRPT hit a ceiling of 24.56% in Q4 2024 and a floor of 948.91% in Q2 2022.
  • Median EBIT Margin over the past 5 years was 33.11% (2025), compared with a mean of 159.94%.
  • Biggest five-year swings in EBIT Margin: soared 78902bps in 2021 and later plummeted -84678bps in 2022.
  • Sarepta Therapeutics' EBIT Margin stood at 52.52% in 2021, then surged by 74bps to 13.75% in 2022, then soared by 117bps to 2.28% in 2023, then skyrocketed by 975bps to 24.56% in 2024, then crashed by -478bps to 92.92% in 2025.
  • The last three reported values for EBIT Margin were 92.92% (Q4 2025), 25.89% (Q3 2025), and 18.91% (Q2 2025) per Business Quant data.